Cue Biopharma(CUE)
SOMERVILLE, MAPharmaceutical
Focus: Cue Biopharma is a public immunotherapy company focused on oncology, developing engineered T-cell therapies for solid tumors. The company operates as a mid-cap biotech with early-stage pipeline programs spanning head and neck cancer, glioblastoma, and colorectal cancer.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Cue Biopharma
AI assessmentNot HiringNo open roles listed right now. Follow Cue Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Cue Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
6 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$9M
FY2025
Pipeline & Clinical Trials
Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
ImmunodeficiencyClinical Trials (1)
NCT05655546ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
N/AHelp build intelligence for Cue Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.